BioNTech Shares Face Dual Challenges as Pfizer Exits and CureVac Vote Looms

BioNTech finds itself navigating turbulent waters this week, caught between significant shareholder actions and a pivotal strategic decision. The German mRNA specialist is confronting two major tests simultaneously that are shaping its near-term market performance and long-term direction.

A crucial vote scheduled for Tuesday, November 25th will determine the fate of BioNTech's proposed acquisition of CureVac. CureVac shareholders are set to decide on the takeover during an extraordinary general meeting, a move that could significantly alter the competitive landscape within the mRNA sector.

Key considerations for investors:

• Portfolio Expansion: Successful acquisition would transfer CureVac's intellectual property assets and research capabilities to BioNTech
• Implementation Hurdles: Market participants express concern about integration complexities and associated costs
• Market Sensitivity: Trading activity is expected to show increased volatility surrounding the decision date

While the long-term strategic benefits appear compelling, the short-term market reaction reflects apprehension about execution risks.

Major Stakeholder Reduces Position

Adding pressure to BioNTech's share price, long-term partner Pfizer has substantially decreased its investment in the company. The pharmaceutical giant sold approximately 4.55 million American Depositary Receipts, representing a dramatic 54.7% reduction in its stake.

This block trade created an immediate supply-demand imbalance that continues to weigh on the stock. Although the operational collaboration on mRNA vaccine development remains intact, financial markets are interpreting Pfizer's divestment as a strategic reallocation of capital. Investors now face the challenge of valuing BioNTech independently as the company transitions into the post-pandemic era.

Should investors sell immediately? Or is it worth buying BioNTech?

The equity has been trading in the €84-85 range recently as market participants seek to establish a new support level.

Financial Performance Presents Contrasting Picture

BioNTech's operational results tell a different story from its recent stock performance. The company reported better-than-expected third quarter 2025 revenue of €1.5 billion, surpassing analyst projections. Management has subsequently raised full-year guidance to between €2.6 and €2.8 billion.

However, these strong top-line figures were accompanied by a net loss of €28.7 million for the quarter. This reflects substantial investments in BioNTech's oncology pipeline, particularly the BNT327 program acquired through the Biotheus transaction. Financial markets currently view BioNTech as undergoing a fundamental transformation—evolving from a COVID-focused cash generator to a diversified cancer therapeutics specialist. This transition requires both time and continued capital investment.

Navigating Competing Pressures

BioNTech currently faces the convergence of technical selling pressure and strategic uncertainty. The €84-85 price level has become a critical technical support zone that will test investor conviction. The company's ability to withstand these simultaneous challenges depends on whether it can successfully convert its substantial cash reserves and strategic acquisitions into commercially viable cancer treatments.

The outcome of Tuesday's CureVac vote may provide near-term direction, but the market may require additional time to fully absorb the implications of Pfizer's significant reduction in ownership.